Loading...
In the latest HIV and ID Observations blog post, Dr. Paul Sax shares thoughts on a study that tested hydroxychloroquine as postexposure prophylaxis for COVID-19. He says: “To say that the recruitment of this post-exposure prophylaxis trial was innovative hardly gives the methods enough credit.”
Want to see more from NEJM Journal Watch? Register here.